{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin",
    "query": {
      "intervention": "Rifaximin"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 79,
    "total_pages": 8,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifaximin&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T05:56:35.017Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00956150",
      "title": "Bacterial Overgrowth Associated With Chronic Multisymptom Illness Complex",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gulf War Syndrome"
      ],
      "interventions": [
        {
          "name": "Lactulose Breath Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Henry C. Lin, MD",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 210,
      "start_date": "2009-04",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-05-01",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00956150"
    },
    {
      "nct_id": "NCT00748904",
      "title": "Rifaximin Versus Lactulose in Renal Failure",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Liver Cirrhosis",
        "Renal Failure"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Lactulose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 0,
      "start_date": "2008-06",
      "completion_date": "2009-07",
      "has_results": false,
      "last_update_posted_date": "2022-02-08",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00748904"
    },
    {
      "nct_id": "NCT01345175",
      "title": "Rifaximin and Placebo in the Treatment of Bowel Dysfunction After Anterior Resection for Rectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rectal Cancer"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 69,
      "start_date": "2011-04-26",
      "completion_date": "2023-03-23",
      "has_results": true,
      "last_update_posted_date": "2024-05-14",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 3,
      "location_summary": "Basking Ridge, New Jersey • Commack, New York • New York, New York",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01345175"
    },
    {
      "nct_id": "NCT02470780",
      "title": "Treating Bacterial Overgrowth in Parkinson's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Parkinson's Disease",
        "Small Intestinal Bacterial Overgrowth"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Cincinnati",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2015-12",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2024-03-01",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02470780"
    },
    {
      "nct_id": "NCT00731679",
      "title": "Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-Constipation Irritable Bowel Syndrome"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2008-07",
      "completion_date": "2009-09",
      "has_results": true,
      "last_update_posted_date": "2019-11-29",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 86,
      "location_summary": "Hueytown, Alabama • Phoenix, Arizona • Sierra Vista, Arizona + 78 more",
      "locations": [
        {
          "city": "Hueytown",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sierra Vista",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00731679"
    },
    {
      "nct_id": "NCT03529825",
      "title": "Rifaximin for Infection Prophylaxis in Hematopoietic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Microbial Colonization"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "2 Years to 21 Years"
      },
      "enrollment_count": 26,
      "start_date": "2018-07-18",
      "completion_date": "2021-09-10",
      "has_results": false,
      "last_update_posted_date": "2021-10-12",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03529825"
    },
    {
      "nct_id": "NCT00281502",
      "title": "The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Encephalopathy",
        "Hepatitis C",
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Rifaximin (drug)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Weill Medical College of Cornell University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2005-12",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2010-11-05",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00281502"
    },
    {
      "nct_id": "NCT05150587",
      "title": "Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Papulopustular Rosacea"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alfasigma S.p.A.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2021-10-05",
      "completion_date": "2022-10-20",
      "has_results": true,
      "last_update_posted_date": "2024-04-24",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 38,
      "location_summary": "Yuma, Arizona • Fort Smith, Arkansas • Long Beach, California + 31 more",
      "locations": [
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05150587"
    },
    {
      "nct_id": "NCT03818672",
      "title": "Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Severe Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Rifaximin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2019-01-29",
      "completion_date": "2020-02-02",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03818672"
    },
    {
      "nct_id": "NCT02124512",
      "title": "Blood Lipopolysaccharide (LPS) Rifaximin Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obese",
        "Insulin Resistance",
        "Metabolic Syndrome"
      ],
      "interventions": [
        {
          "name": "Rifaximin SSD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Philip Kern",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "35 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "35 Years to 65 Years"
      },
      "enrollment_count": 12,
      "start_date": "2015-03",
      "completion_date": "2019-05-31",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-09-03T05:56:35.017Z",
      "location_count": 1,
      "location_summary": "Lexington, Kentucky",
      "locations": [
        {
          "city": "Lexington",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124512"
    }
  ]
}